Inside a study in breast cancer cells, the combination of lapatinib, a twin HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented the two HER2 and HER3 phosphorylation induced by INK128 and produced synergistic induction of cell Dying in different HER2-good cell strains immune to trastuzumab and lapatinib. In vivo https://hamidb974rwa7.wikipublicist.com/user